AP
BMRN icon

Americana Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Americana Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200
Closed -$16K – 156
2019
Q4 		$16K Buy
+200
New +$15.1K 0.01% 383

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Americana Partners's BMRN Position: Q1 2020 in Review

Americana Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2020, closing a stake of 200 shares — an estimated $16K sold.

Americana Partners first reported a position in BMRN in Q4 2019 and held it in 1 quarter. The position peaked at $16K in Q4 2019. 500 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

  • Americana Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Americana Partners sold 200 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $16K.
  • Americana Partners first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Americana Partners's BioMarin Pharmaceuticals position peaked at $16K in Q4 2019.
  • 500 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on Americana Partners's 13F filing for Q1 2020, filed 12 May 2020.